Latest News

Nov 21, 2022

DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics

In a recent interview with DeciBio, June Park, CEO of siRNAgen, covered a wide range of topics such as the rapid growth in the siRNA market, expanding RNAi indication areas, and rise of globalization

Sep 29, 2022

siRNAgen Awarded Johnson & Johnson Innovation Seoul Innovation QuickFire Challenge

Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce siRNAgen as an Awardee of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

Sep 15, 2022

siRNAgen Therapeutics joins Endless Frontier Labs

siRNAgen Therapeutics has been selected to join the Endless Frontier Labs 2022-2023 cohort. This year’s 75 ground-breaking companies were selected amongst a competitive pool of over 1,000 applicants. siRNAgen will be joining as one of 26 that have been selected for the Life Sciences Track.